AKAndrea Kröger

Andrea Kröger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrea Kröger has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • David Andrés Nocera

    Department of Clinical Biochemistry, Faculty of Chemical Sciences, Center for Research in Clinical Biochemistry and Immunology, National University of Cordoba , X5000HUA Córdoba

    1 shared publication
  • Emiliano Roselli

    Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

    1 shared publication
  • Gabriel Morón

    Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) Argentina

    1 shared publication
  • Gerardo Gatti

    Department of Clinical Biochemistry, Faculty of Chemical Sciences, Center for Research in Clinical Biochemistry and Immunology, National University of Cordoba , X5000HUA Córdoba

    1 shared publication
  • Jadwiga Jablonska

    Department of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, Essen, Germany

    1 shared publication
  • Mariana Maccioni

    Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Centro de Investigaciones en Bioquímica Clínica e Inmunología, Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad Nacional de Córdoba, Córdoba, Argentina

    1 shared publication

Latest Publications

  • Open Access

    In Vivo Visualizing the IFN-β Response Required for Tumor Growth Control in a Therapeutic Model of Polyadenylic-Polyuridylic Acid Administration

    by David Andrés Nocera, Emiliano Roselli, Paula Araya, Nicolás Gonzalo Nuñez, Stefan Lienenklaus, Jadwiga Jablonska, Siegfried Weiss, Gerardo Gatti, Melanie M. Brinkmann, Andrea Kröger, et al.

    The crucial role that endogenously produced IFN-β plays in eliciting an immune response against cancer has recently started to be elucidated. Endogenous IFN-β has an important role in immune surveillance and control of tumor development. Accordingly, the role of TLR agonists as cancer therapeutic agents is being revisited via the strategy of intra/peritumoral injection with the idea of stimulating the production of endogenous type I IFN inside the tumor. Polyadenylic-polyuridylic acid (poly A:U) is a dsRNA mimetic explored empirically in cancer immunotherapy a long time ago with little knowledge regarding its mechanisms of action. In this work, we have in vivo visualized the IFN-β required for the antitumor immune response elicited in a therapeutic model of poly A:U administration. In this study, we have identified the role of host type I IFNs, cell populations that are sources of IFN-β in the tumor microenvironment, and other host requirements for tumor control in this model. One single peritumoral dose of poly A:U was sufficient to induce IFN-β, readily visualized in vivo. IFN-β production relied mainly on the activation of the transcription factor IFN regulatory factor 3 and the molecule UNC93B1, indicating that TLR3 is required for recognizing poly A:U. CD11c+ cells were an important, but not the only source of IFN-β. Host type I IFN signaling was absolutely required for the reduced tumor growth, prolonged mice survival, and the strong antitumor-specific immune response elicited upon poly A:U administration. These findings add new perspectives to the use of IFN-β–inducing compounds in tumor therapy.